Cytodyn Inc (CYDY)

[$5.95akadawson-m]

Wait a second - this is a double-edge sword answer. You can't have it both ways.

Let's look at what you wrote:

"Why should any drug fit for public consumption be "surprisingly safe." Shouldn't the drug, any drug fit for public consumption be safe?

What results clinically prove that Leronlimab is actually beneficial?

Dr. Scott Kelly said "anecdotes don't get out of bed," but anecdotes aren't clinically recorded results from a study are they?"


First of all, Leronlimab has not been approved by the FDA, therefore it is not classified as anything. It is not fit for "MASS" public consumption. It is only EIND acceptable. In other words, take it at your own risk or better yet, it is the last thing one should take, called RTT - Right to try.

Now, the results have only been recorded in RTT cases and if that sick/dying patient only was suffering from COVID, that patient experienced the Lazarus syndrome after 3-6 days and went home. Yes, that is an anecdote, a living-breathing-surviving anecdote. Is this not beneficial?

I would not admonish someone for saying that Leronlimab works. The standard definition of "what results clinically prove that Leronlimab is actually beneficial?"Well, there are many Lazarus-types walking around. They have been described in newspaper reports - they arose from their deathbed! An unapproved drug that saves lives, yet an unapproved drug will not have verifiable results because it is unapproved. So, this is where that paradigm, "both ways" kicks in.

There are at least 70,000 reasons why people have invested in Leronlimab. They have invested in basically, an anecdote because it is an unapproved drug. Yet it is the only one that consistently turns the walking dead into the replenished.

Clinically proven results do not matter. Would I take Leronlimab if I were dying even if it's an anecdote? I'm sure you know the answer.